In December 2025, J.P. Morgan upgraded Recursion Pharmaceuticals after REC-4881 showed rapid, durable polyp burden reductions and a favorable safety profile in familial adenomatous polyposis patients, ...

The following slide deck was published by Recursion Pharmaceuticals, Inc. in conjunction with this event.

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a ...

Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...

Given the importance of recursion in modern linguistics, there ought to be much to commend in Watumull et al.'s (2014) attempt to clarify what recursion is (or ought to be); I have trudged this very ...

The last time I wrote about Recursion Pharmaceuticals (RXRX), it was with respect to a Seeking Alpha article entitled "Recursion: CDK7 Differentiation Is Initially Paying Off." With respect to this ...

In his 1960 book Theory and Design in the First Machine Age, the critic and historian Reyner Banham presciently noted a growing chasm between technological change and the capacity of designers to ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Beijing Zhongke Journal Publising Co. Ltd. The lead author Cheng-Zhi Qin, a professor of geographical information science (GIS) at Institute of Geographic Sciences and Natural Resources Research, ...

Recursion, a clinical-stage TechBio company, is set to present preliminary data from its Phase 1b/2 clinical trial, TUPELO, at the 2025 Digestive Disease Week (DDW) meeting on May 4, 2025, in San ...